Our Pick Of The Best Penny Stocks In October 2026
When consumer prices rise faster than worker paychecks, every dollar has to work harder. That pressure often pushes investors to look beyond the crowded big-cap space and toward lower priced shares of financially sound smaller businesses that may offer more room for upside per dollar invested. This article zeroes in on three such lower priced stocks that pass strict balance sheet and cash discipline filters.
The three stocks highlighted here offer a compelling starting point if you want exposure to lower risk early-stage businesses built on stronger balance sheets. However, if you want the absolute best, these 11 elite penny stocks are the cream of the crop.
GoodRx Holdings (GDRX)
Overview: GoodRx Holdings runs a prescription price comparison and savings platform that helps US consumers and pets access lower out of pocket drug costs.
Operations: GoodRx generates US$785 million from healthcare software in the United States, with its prescription savings and related digital health services as the sole reported segment.
Market Cap: US$1.18b
GoodRx Holdings fits the Financially Fit Penny Stocks theme because its core price comparison tool directly targets lower prescription bills for households while keeping the business model asset light and focused on cash generative healthcare software and subscriptions.
"GoodRx's entry and rapid expansion in the high-growth subscription market (beginning with erectile dysfunction and soon scaling to weight loss and hair loss) positions it to capture large, recurring revenue streams with far higher gross margins than transaction-based business, accelerating earnings and margin expansion.
What happens to GoodRx’s appeal if one unseen pressure on how much pharmacies share from each discounted script starts to shift?
If that pressure point matters to you, read the full narrative for GoodRx Holdings to see how GoodRx Holdings could still accelerate or stall as the model evolves.
Nuvation Bio (NUVB)
Overview: Nuvation Bio is a New York based oncology biotech developing clinical stage cancer drugs, including IBTROZI for ROS1+ lung cancer and safusidenib for IDH1 mutant brain tumors, which fits the Financially Fit Penny Stocks theme through its early stage pipeline focus and smaller market footprint.
Operations: Nuvation Bio generates about US$169.9 million from oncology development activities, with roughly US$124 million from the United States, US$30 million from Japan and US$16 million from China.
Market Cap: US$1.66b
For investors scanning the Financially Fit Penny Stocks screener for smaller healthcare players with meaningful clinical assets, Nuvation Bio offers a focused oncology story built around late stage programs that are already shaping real world treatment patterns and expectations.
"IBTROZI is rapidly emerging as the preferred therapy in ROS1 positive non small cell lung cancer, with best in class durability, strong brain penetration and growing first line use. This positions the drug to drive sustained prescription growth and expanding recurring revenue over many years."
What happens to that long term oncology cash engine if global access, pricing power, or trial timelines shift even slightly off script?
If those fault lines around pricing power matter to you, read the full narrative for Nuvation Bio to see how Nuvation Bio could still accelerate or stall from here.
Grab Holdings (GRAB)
Overview: Grab Holdings runs a Southeast Asian superapp that combines transport, deliveries, digital payments and GrabFin lending products for consumers and small businesses.
Operations: Grab generates about US$3.7b in annual revenue, mainly from Deliveries at US$1.99b, Mobility at US$1.31b and Financial Services at US$430 million.
Market Cap: US$12.15b
Grab Holdings matters for the Financially Fit Penny Stocks theme because GrabPay and GrabFin link ride-hailing and food delivery users directly into digital payments, PayLater and micro-lending. These are built on a balance sheet that aims to support scalable credit rather than high churn borrowing.
"Financial Services may eventually become Grab's second economic engine. Revenue there increased 59%, while the segment's adjusted EBITDA loss narrowed from $26 million to $15 million."
The real test comes if one unresolved funding and cash flow pressure starts to bite just as that second engine is ready to scale.
If that concern is on your mind, the full narrative for Grab Holdings shows how Grab Holdings could balance funding needs with an accelerating superapp engine.
Seeking Fresh Alternatives Before They Fly
Fresh opportunities do not stay quiet for long. Once momentum hits, entry points can move quickly. Scan these curated ideas while they are still under the radar for now and consider them early.
- Identify sturdier balance sheets before momentum traders arrive by running the list of solid balance sheet and fundamentals (25 results) so you can focus on businesses built to handle shocks.
- Explore structural demand in digital money by tapping into 18 cryptocurrency and blockchain stocks while these infrastructure stocks may still reflect early adoption rather than peak enthusiasm.
- Assess potential opportunities related to electricity and data needs by screening 43 power grid technology and infrastructure stocks and focusing on the grid enablers that help keep systems running.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com